Compared effects of natriuretic peptides on ovalbumin-induced asthmatic model.
We compared the effects of natriuretic peptides on antigen-induced bronchoconstriction and airway microvascular leakage in sensitized guinea pigs. Anesthetized male guinea pigs, ventilated via a tracheal cannula, were placed in a plethysmograph to measure pulmonary mechanics for 10 min after challenge with 1 mg/kg of ovalbumin, and then Evans blue dye was extravasated into airway tissue in order to indicate and evaluate microvascular leakage. Three separate intravenous pretreatments using atrial natriuretic peptide (ANP), brain natriuretic peptide (BNP), and C-type natriuretic peptide (CNP) significantly inhibited the ovalbumin-induced bronchoconstriction and microvascular leakage in a dose-dependent manner. These inhibitory effects were mimicked by 8-bromoguanosine 3',5'-cyclic monophosphate. We showed that the rank order of inhibitory potencies, which were mediated by cyclic guanosine 3',5'-monophosphate, was BNP > or = ANP > or = CNP. These results gave us some clues for the clinical application of the natriuretic peptides.
Ohbayashi
H
H
Second Department of Internal Medicine, Nagoya University School of Medicine, Japan.
Suito
H
H
Takagi
K
K
D000818:Animals; D000941:Antigens / Q000494:pharmacology; D001249:Asthma / Q000139:chemically induced / Q000188:drug therapy*; D009320:Atrial Natriuretic Factor / Q000494:pharmacology / Q000627:therapeutic use*; D001794:Blood Pressure / Q000187:drug effects; D001980:Bronchi / Q000098:blood supply / Q000187:drug effects; D016084:Bronchoconstriction / Q000187:drug effects; D002199:Capillary Permeability / Q000187:drug effects; D006152:Cyclic GMP / Q000031:analogs & derivatives / Q000494:pharmacology; D004195:Disease Models, Animal; D006168:Guinea Pigs; D017998:Leukotriene D4 / Q000494:pharmacology; D008297:Male; D020097:Natriuretic Peptide, Brain; D020098:Natriuretic Peptide, C-Type; D009419:Nerve Tissue Proteins / Q000494:pharmacology / Q000627:therapeutic use*; D010047:Ovalbumin / Q000494:pharmacology*; D011506:Proteins / Q000494:pharmacology / Q000627:therapeutic use*; D014132:Trachea / Q000098:blood supply / Q000187:drug effects
D000941:Antigens; D009419:Nerve Tissue Proteins; D011506:Proteins; D020097:Natriuretic Peptide, Brain; D020098:Natriuretic Peptide, C-Type; C016276:8-bromocyclic GMP; D017998:Leukotriene D4; D009320:Atrial Natriuretic Factor; D010047:Ovalbumin; D006152:Cyclic GMP